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1. Introduction
Gastric inflammation is highly complex biochemical protective response to the cellular tis‐
sue injury. Chronic gastritis is associated with the inflammatory cellular infiltrate predomi‐
nantly consisting of lymphocyte and plasma cells in gastric mucosa. Many evidences
suggest that Helicobacter pylori (H. pylori) infection and non steroidal anti- inflammatory
drug (NSAID) ingestion are major causative factors. Both are highly implicated in the patho‐
genesis of gastric mucosal oxidative injury in humans.
Chronic gastritis is mainly divided into two main categories namely non-atrophic and atro‐
phic gastritis (Rugge et al, 2011). In the gastric mucosa, atrophy is defined as the loss of ap‐
propriate glands. Atrophic gastritis, resulting mainly from long standing H. pylori infection
and is a major risk factor for the onset of gastric cancer.
Two main types of atrophic gastritis can be recognized, one characterized by the loss of
glands, accompanied by fibrosis or fibromuscular proliferation in the lamina propria and
the other characterized by the replacement of normal mucosa into an intestinal type of mu‐
cosa i.e intestinal metaplasia (Rugge et al, 2007).
Helicobacter pylori is spiral –shaped, flagellated, Gram-negative bacterium. It colonizes the
stomach of about 50 percent of the world population, especially in the developing countries
(Marshall BJ and Warren, 1983, Bruce and Maaroos, 2008). It is directly implicated in the
dyspepsia, acute and chronic gastritis, peptic ulceration, MALT lymphoma and it is an inde‐
pendent risk factor for gastric adenocarcinoma (Atherton, 2006). It may also be a risk factor
for pancreatic including cancer (Trikudanathan et al, 2011). H. pylori has been also associat‐
ed to some extra-gastric diseases including several autoimmune diseases.
© 2013 Elseweidy; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Geographical distribution of the prevalence of H. pyloriinfection
The prevalence of H. pylori infection varies from country to country with large differences
between developed and developing countries (Neunert et al, 2011) The epidemiology of H.
pylori infection in developing countries is characterized by a rapid rate of acquisition of the
infection such that approximately 80 percent of the population is infected by the age of 20
(Robinson et al, 2007) because the disease is most often acquired in childhood or when
young children are present in the household. The prevalence of H. pylori is inversely related
to socioeconomic status (Sobala et al, 1991, Blaser and Atherton, 2004).The major variable be‐
ing the status childhood, the period of highest risk. Attempts to understand the different in‐
fection rates in defined groups have focusedon differences in socioeconomic states defined
by occupation, family income level and living conditions. Each of these variables measures a
different component of the socioeconomic complex.
3. Routs of transmission
H. pylori is a true opportunistic bacterium that will use any method available for gaining
access to the human stomach. Gastro-oral (e.g. exposure to vomit) and fecal-oral routs are
believed to be the primary means of transmission. The bacterium can also be transmitted
through exposure to contaminated food or water. The majority of the data support the no‐
tion that transmission is mainly within families. Thus close contact and the level of house
hold sanitation appear to be the most important variables. These findings may support the
concept that the most likely sources of transmission are person-to-person and /or exposure
to a common source of infection.
H. pylori from the Hispanic families living in certain place was examined for relatedness
based on the geno types using the cag A, vac A and ice A genes. H. pylori isolated from the
children and their mothers had the same genotype and were different from the associated
with children’s fathers or brothers-in-law (Graham et al, 2004). The high rate of transmission
to spouses also suggests that genetic factors are less critical than living conditions for trans‐
mission of the bacterium.
4. Relationship between H. pylori infection and associated diseases
AS reported before H. pylori infection causes chronic gastritis, peptic ulcer disease, primary
gastric B-cell lymphoma, (indirectly) gastric adenocarcinoma and patients with infection de‐
velop gastric damage (Harford et al, 2000, Nomura et al, 2002). Approximately 17 percent of
infected patients develop peptic ulcer and one quarter of such patients experience an ulcer
complication (Crabtree et al, 1991, Censini et al, 1996). Numerous trials have shown that ul‐
cer relapse is prevented following infection cure (Yamaoka et al, 1998, Yamaoka et al, 1999).
Histological and serologic studies have also shown that the infection preceded the ulcer and
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H. pylori infection is now accepted as one of the major causes of peptic ulcers (the other be‐
ing use of non-steroidal anti-inflammatory drugs) (Higashi et al, 2002).Accordingly develop‐
ment of the disease depends on bacterial, host and environmental factors.
The risk of ulceration is higher with more virulent strains. The best described virulence de‐
terminants are expression of active forms of a vacuolating cytotoxine (Vac A)(Crabtree et al,
1995) and possession of a protein secretory apparatus called cag (cytotoxin-associated gene
products) that stimulates the host inflammatory response (Ando et al, 2002). Cag+ strains in‐
teract more closely with epithelial cells and induce release of pro-inflammatory cytokines,
thereby increasing inflammation.
However it is unclear whether it is this or the direct translocation of a bacterial protein (Cag
A) into gastric epithelial cells that is the primary cause of the disease, including gastric ade‐
nocarcinoma.
Host genetic susceptibility and environmental factors also affect disease risk; for example,
smoking is strongly associated with peptic ulceration in H. pylori –infected individuals. H.
pylori induced duodenal ulceration arises in people with antral predominant gastritis (Back‐
ert et al, 2004, Majumdar et al, 2010). Antral inflammation leads to reduced somatostatin
production and, because somatostatin has a negative feedback effect on gastrin production,
this results in hypergastrinaemia. Gastrin stimulates enterochromaffin-like cells to release
histamine, which acts on parietal cells, resulting in stimulated acid production, increased
duodenal acid load and the formation of protective gastric metaplasia in the duodenum.
Helicobacter pylori cannot colonize the normal duodenum, but can colonize gastric meta‐
plasia, causing inflammation and ulceration (Majumdar et al, 2010). Hypergastrinemia on
the other hand and inconsequence to antral inflammation may leads to an increase of acid
production from the acid secreting areas of the stomach in response to food and other stimu‐
li. The resulting increased acid load in the duodenum is one factor encouraging duodenal
ulceration. Gastric ulceration occurs on a background of pangastritis often arising at the
highly inflamed transitional zone between antrum and corpus, particularly on the lesser
curve.
5. Clinical features
Chronic H. pylori –associated gastritis per se is asymptomatic but the initial acquisition of
the infection cause acute gastritis with hypochlorhydria which may cause abdominal pain,
nausea and vomiting that resolve within a few days (Fischer et al, 2001). Uncomplicated
peptic ulcers typically cause epigastric pain and less commonly, nausea, vomiting and
weight loss, whereas some ulcers (particularly NSAID ulcers) are asymptomatic. The classi‐
cally described pain of duodenal ulcer is felt as a growing or burning sensation, often with a
relation to meals; occurring 1-3 hours after meals and /or at night and relieved by food. Gas‐
tric ulcer pain is instead often precipitated by food. However symptoms are actually very
poorly discriminatory for ulceration site and even for whether or not an ulcer is present. Ex‐
amination usually reveals epigastric tenderness but may be normal.
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6. Complications
H. pylori ulcers usually heal and relapse spontaneously but ulcers of any cause, and particu‐
larly NSAID –induced ulcers, may cause serious complications.
Acutely bleeding ulcers cause anemia, perforation results in peritonism and gastric outlet
obstruction causes persistent vomiting. The discovery of H. pylori therefore has revolution‐
ized the management of peptic ulcers; its eradication heals H. pylori –induced ulcers and
prevents their relapse.
7. Dyspepsia in the community
Older patients presenting for the first time and those with alarm symptoms or signs (weight
loss, dysphagia, persistent vomiting, gastrointestinal bleeding, unexplained anemia, epigas‐
tric mass, previous gastric ulcer or gastric surgery) should be referred for upper gastrointes‐
tinal endoscopy and /or other investigations, both to exclude malignancy and to make a
positive diagnosis. Other patients (with simple dyspepsia) should normally be treated with‐
out endoscopy or specialist referral. These patients should have one of two initial ap‐
proaches. In populations where H. pylori prevalence is high (≥ 20-25 percent), patients
should be tested for H. pylori non-invasively, and given treatment to eradicate H. pylori if
positive.
In populations with lower H. pylori prevalence another approach may be followed (inhibi‐
tors). In either case, if the first approach fails, the second can be tried (Wirth et al, 1998, Ma‐
son et al, 2005, Delaney et al, 2008).
8. Upper gastrointestinal endoscopy
Upper gastrointestinal endoscopy is the investigation of choice in older patients with dys‐
pepsia and those with alarm symptoms because it enables diagnosis of ulceration and of
other macroscopic abnormalities such as malignancy and Oesophagitis. Histological exami‐
nation of gastric mucosal biopsy specimens is useful in confirming the nature of any abnor‐
malities seen, and in identifying whether gastritis is present and its cause. However it is
seldom necessary if macroscopic appearances are normal. Treatment with acid –suppressing
drugs before endoscopy may heal ulcers, rendering endoscopic findings misleading since
proton pump inhibitors, bismuth compounds and antibiotics may cause false-negative H.
pylori tests. If possible, acid suppressing agents should be avoided for at least two weeks
and preferably 4, bismuth compounds and antibiotics may be avoided for at least 4 weeks
before endoscopy.
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9. H. pylori infection and oxidative stress expression
Oxidative stress is associated with many diseases (Yamaoka et al, 2000), including gastric
disorders like chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lym‐
phoid tissue (MALT) lymphoma (Majumdar et al, 2010). These gastric diseases can be the
result of infection with Helicobacter pylori, which is believed to be the major etiological age
(Chen et al, 2005). Several studies have been carried out focusing bacterial factors in gastric
diseases and it has been assumed that H. pylori strains having Cag A+ /VacAs1 genotype
are more virulent than other genotypes.
Some studies have reported that Vac As1 strain is usually toxigenic and tends to be CagA+
(Moss et al, 1992).
H. pylori infection induces an inflammatory response that is also oxidative. The gastric epi‐
thelium and the bacteria induce production of interleukin-8 (IL-8) that contributes to the
generation of great amounts of toxic reactive oxygen species (ROS), with marked infiltration
of inflammatory cells and can elicit induction of interleukin-1β (IL-1β), interleukin -6 (IL-6),
IL-8, IL-12, tumor necrosis factor-α (TNF-α) and interferon-γ (INF-γ) (Marshall et al, 1985).
The inflammatory response induced during H. pylori infection does not appear to confer
protective immunity and the resulting oxidative burst caused by phagocytic cells can dam‐
age gastric tissues (Graham et al, 2004). Increased pathogen- inducible nitric oxide synthase
(iNos) has also been observed in the gastric mucosa of the patients with duodenal ulcer
(2010), gastric cancer (Mason et al, 2005), gastritis (Delaney et al, 2008) caused by H. pylori
infection. iNos is induced by a variety of stimuli, including bacterial Lipopolysaccharide, cy‐
tokines and products from the bacterial wall (Janssen et al, 1992) and its expression contrib‐
utes to oxidative stress.
Another oxidative enzyme induced by H. pylori in gastric disease is Nox1 (NADH oxidase
1) (Blaser and Atherton, 2004). It constitutively produces both superoxide anion and Hydro‐
gen peroxide (H202). Increased expression of Nox1 mRNA moderately increases superoxide
generation, which leads to a reduction in aconitase activity, making Nox1 a good marker of
oxidative stress (Tandon et al, 2004).H. pylori also induces ROS production by gastric epi‐
thelial cels, contributing to increased damage in the mucosa (Naito and Yoshikawa, 2002)
and H. pylori itself generates great amounts of superoxide anions to inhibit bactericidal ac‐
tion of nitric oxide (N0) produced by inflammatory cells (Atherton, 1997).
Another source of ROS that contributes to oxidative stress is the H202 generated by TNF-α
and other cytokines that are essential for their activity (Atherton et al, 1995) since H202 in
the presence of ferrous or cuperous ions can catalyzes the generation of the highly reactive
hydroxyl radical by Fenton reaction (Noach et al, 1994), an increase in H202 concentration
induced by cytokines makes also TNF-α expression a good oxidative stress marker.
TNF-α is produced by a wide variety of cell types and it is positively regulated under stress
and pathological conditions (Meyer et al, 2000). Protection of cells against ROS is accom‐
plished through the activation of oxygen-scavenging enzymes such as superoxide dismutase
(SOD), glutathione peroxidase (GPX) and catalase (CAT).
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However it is not well known how H. pylori bacteria products and inflammation affect the
ability of gastric cells to protect themselves from damage caused by ROS. The virulence of
the strain acts primarily as an accelerator in the disease process and not as a predictor of
outcome.
10. The immune response to H. pylori
H. pylori is an active stimulator of both the innate and acquired immune responses. Local
innate recognition of H. pylori by epithelial cells is thought to be an important disease deter‐
minant. There are also strong local and systemic antibody and cell-mediated immune re‐
sponse
11. The innate immune response
H. pylori colonization of the gastric mucosa triggers innate host defense mechanism thus
stimulating the expression of pro-inflammatory and anti-bacterial factors by gastric epithe‐
lial cells (Antos et al, 2001). The first line of defence results in gastritis and H. pylori also
stimulates innate immune responses from these infiltrating cells (Kawahara et al, 2001)
which may subsequently influence bacterial colonization density (Arnold et al, 2001), the in‐
flammation level and also the generation of adaptive response may represent a central de‐
terminant of disease severity and participation is thought to be a major mediator in gastric
carcinogenesis.
12. Antimicrobial peptides
Secreted antimicrobial peptides, including defensins are produced as part of the innate im‐
mune response to H. pylori. Elevated levels of human β defensin (hBD2) and the neutrophil-
derived alpha defensins 1,2 and 3 are present in the gastric juice of H. pylori –infected
patients (Nagata et al, 1998) and increased expression of hBD2 (Beutler and Cerami,
1986),hBD3 (Meneghini, 1998), adrenomedullin (Jung et al, 1997), angiogenin (George et al,
2003) and the human cationic antimicrobial peptide 18 (Gobert et al, 2004) LL-37 (Harris et
al, 1998) has been shown in infected human gastric epithelial cells.
13. The acquired immune response
H.  pylori  infection  provokes  a  vigorous  humoral  and  cellular  immune  response  in  hu‐
mans,  but  the organism is  rarely eliminated from the gastric  mucosa and infection per‐
sists  lifelong in  the absence of  treatment  (Blaser  and Atherton,  2004).  One possibility  is
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that  H.  pylori  itself  influences  the  immune response  to  avoid  its  own clearance  by  the
host  and to  down-regulate  excessive  host  damage  thus  promoting  a  relatively  peaceful
co-existence.  However,  there is  good evidence that  the acquired immune response itself
contributes  to  gastro-duodenal  disease  processes  (Zevering  et  al,  1999).  Mouse  models
have  shown  that  the  cellular  immune  response  is  a  central  regulator  of  H.  pylori-in‐
duced gastric inflammation and pathology. Mice deficient in IL-10 mount a vigorous in‐
flammatory  response  to  H.  pylori,  successfully  and  rapidly  clear  H.  pylori  infections
(Chen et al, 2001).
14. Humoral immunity
H. pylori stimulates the production of mucosal and systemic IgA and IgG s, but the effect of
antibody upon bacterial colonization remains controveial. One report showed that the intra-
gastric administration of specific monoclonal IgA mediated protection against H.fellis infec‐
tion in mice (George et al, 2003). In contrast, others have shown that specific IgA and IgG in
mice actually promote bacterial colonization and reinhibit protective immune mechanisms
(Akhiani et al, 2004, Akhiani et al, 2005). H. pylori is susceptible to the compliment-mediat‐
ed bactericidal activity of serum (Gonzalez-Valencia et al, 1996) but it is possible to success‐
fully immunize B-cell deficient mice (Ermak et al, 1998, Sutton et al, 2000), indicating that
antibodies are not essential for protection. The B-cell response plays an important role in
pathogenesis through participating in an H. pylori –precipitated autoimmune process
(D'Elios et al, 2004). In this, antibodies cross-react with host antigens such as those on gastric
epithelial cells and the parietal cell H+,K+_ATPase(Amedei et al, 2003), potentially inducing
local- inflammation and damage.
15. The T-cell response
In humans, the T-cell response to H. pylori is dominated (Fan et al, 1994, Bamford et al,
1998). Th1 cells produce IFNγ and this type of response is associated with pro-inflamma‐
tory cytokine expression, for example TNFα, IL-12 and IL-18. When macrophages are acti‐
vated in the presence of such type I cytokines, the resulting " angry " macrophages secrete
pro-inflammatory factors and have enhanced bactericidal activity compared to those acti‐
vated in  the  presence  of  Th2 cytokines  (Ma et  al,  2003).  The  number  of  IFNγ-secreting
cells  in the infected human gastric  mucosa correlates with the severity of  gastritis  (Leh‐
mann et al, 2002). IFNγ itself appears to be a key mediator, as infusion into mice, even in
the absence of H. pylori infection, induces pre-cancerous gastric atrophy, metaplasia and
dysplasia (GeaCui,  2003).  Some strains of mice,  such as C57BL/6,  which mount a strong
Th1 response to H. pylori,  have more severe gastritis but reduced colonization densities
(Gerhart et al, 2000)
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16. Tests for H. pylori
16.1. Tests not requiring endoscopy
Serology:serological tests involve detection of IgG antibodies against H. pylori and the best
are very accurate. However, accuracy depends critically on the precise serological test used.
Serology may remain positive for years after successful eradication of H. pylori and there‐
fore is not used for checking the treatment success, it is cheap (Majumdar et al, 2010)
Urea breath test (UBT): the UBT is a simple, non invasive test based on H. pylori urease. It is
particularly useful for checking the success of treatment. It is also more accurate than serolo‐
gy and often used as a first-line diagnostic test in places where it is readily available. It must
be performed at least 4 weeks after any bismuth compounds, antibiotics or proton pump in‐
hibitors have been stopped. If not, false-negative results are common. It is inexpensive and
readily available to general practioners in most countries.
Stool antigen test:It is more developed as alternative to the urea breath test (Gisbert et al,
2006). Like the latter it assesses active infection and so can be used for assessing treatment
success since it is less expensive than the UBT.
16.2. Test requiring endoscopy
Biopsy UREASE TEST: The biopsy is placed in a urea solution or gel with a PH indicator.
When H. pylori is present, the urea is hydrolysed by its urease, resulting in a color change.
Some positive results may be available within minutes, although initially negative tests
must be kept for 24 hours to avoid occasional false-negative results. Blood in the upper GIT
may also sometimes cause a false-negative test. The biopsy urease test is cheap and widely
available
Histology: H. pylori infection can be diagnosed accurately by histology if special stains are
used. The distribution of gastritis may give information on disease risk if biopsies are taken
from antrum and corpus (Figure 1)
Histology can also give further information, for example on whether gastric atrophy or in‐
testinal metaplasia- markers of increased risk of gastric adenocarcinoma- are present. Histol‐
ogy is relatively expensive, particularly if special stains are used (Figure 2)
Culture: Endoscopic mucosal biopsy specimens can be cultured for H. pylori. Although
some studies referred to it as being not useful as a purely diagnostic test as H. pylori is not
straightforward to grow, and culture is often falsely negative. However success rates are
high in others, isolates obtained from biopsy of certain individuals having positive IgM se‐
rologically were used for induction of gastritis in experimental rats (Elseweidy et al, 2010).
The serum concentrations of pepsinogen 1 and 11 (Pg1, Pg11), gastrin (G17) and HP anti‐
bodies of IgG class have been used to assess the risk of atrophic gastritis and to differentiate
between HP-related and non HP- related gastritis (Elseweidy et al, 2010).
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Figure 1. Zones of antrum and corpus-fudic glands of the stomach
Figure 2. Distribution of parietal and chief cells of normal tissues (H&E stain)
To verify such concept, certain clinical study was designed mainly to identify the pattern of
chronic gastritis and the potential effect of HP infection. Certain biomarkers, histological
and immunochemical tests were used for assessment.
Fifty eight patients, clinically diagnosed as having chronic gastritis (median age 45 y; range
38-52 y, 9 females, 49 males) were participated in the present study. They were categorized
into two groups.
The first one 31 percent demonstrated positive reaction to IgM- Ab of HP (≥ 40 u/ml) and the
second group 69 percent demonstrated negative reaction. All the patients had signs of
chronic gastritis which vary between them like abdominal pain, heartburn, vomiting or nau‐
sea, flatulence or chronic dyspepsia, epigastric pain or nausea, constipation and anorexia
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(Robinson et al, 2007). Fasting blood samples were collected from the patients before their
direction to endoscopy procedure of the upper GIT with gastric biopsies. Blood samples
were directed for the determination of serum gastrin (G-17), Pepsinogens (Pg1,Pg11), Pros‐
taglandin (PGE2) and Interleukin 6(IL -6).Immunohistochemistry technique was also done
in antral biopsy to demonstrate the expression of INOS, Nitrotyrosin, DNA fragmentation,
myeloperoxidase and histopathological examination (Elseweidy et al, 2010)(Figures 3,4).
Serum gastrin, Pg1, 11, PGE2, IL-6 demonstrated significant increase in gastritis patients as
compared to normal individuals. Sector of HP patients having +veIgM showed significant
increase of Pg1, 11 and slight increase of IL-6 as compared to negative sector
Immunostaining tests in antral biopsy showed strong positive reaction for the above men‐
tioned markers as compared to IgM negative group which demonstrated mild positive reac‐
tions (Figure 5)The study concluded that gastritis patients who express positive IgM for HP
infection showed higher gastrinaemia and more pronounced atrophic, inflammatory and
apoptotic damage than those not expressing IgM- Ab(Elseweidy et al, 2010).
 (a) (b) 
Figure 3. Histological section of human fundic gland of patient suffering from gastritis with anti H. pylori IgM positive
group showing (a) x100 irregular short fundic gland (FG), wide gastric pit (GP), multiple inflammatory cells (arrows)
and blood vessels (double arrows) filling lamina propria (LP), (b) x400 showing irregular simple columnar epithelium
(E), small pyknotic nuclei (arrows) of cells lyningfundic gland (FG) and multiple inflammatory cells (double arrows) fill‐
ing lamina propria (LP)(Elseweidy et al, 2010).
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 (a) (b) 
(c) (d) 
Figure 4. Immunostaining section of Gastritis patients IgM(+) category for (a) nitrotyrosine showing strong positive
reaction in the epithelial (E) lining fundic gland (FG) and inflammatory cells (arrows) filling lamina propria (LP), (b)
myeloperoxidase showing strong positive reaction in the surface columnar epithelial cells (E) and other cells (arrows)
lining fundic gland (FG) (c) iNOS showing strong positive reaction in the inflammatory cells rows) filling lamina propria
(LP), (d) DNA fragmentation factor (DFF) showing strong positive reaction in the epithelial (arrows) lining fundic gland
(FG) and inflammatory cells (double arrows) fill lamina propria (LP) (x200)(Elseweidy et al, 2010).
 (a) (b) 
(c) (d) 
Figure 5. Immunostaining section of human fundic gland from gastritis patients, with anti-H. pylori IgM(-) showing for
(a) nitrotyrosine negative reaction in the epithelial (E) lining fundic gland (FG) and inflammatory cells (arrows) filling
lamina propria (LP), (b) myeloperoxidase showing strong positive reaction in the inflammatory cells (arrows) infiltrat‐
ing lamina propria (LP) (c) iNOS showing moderate positive reaction in the cells of the fundic gland (arrows), (d) DNA
fragmentation factor (DFF) showing mild positive reaction in the epithelial cell (arrows) lining fundic gland (FG) (x20)
(Elseweidy et al, 2010).
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17. Eradication of Helicobacter pylori
First –line treatment is usually a 1 or 2-week triple combination therapy comprising twice-
daily use of omeprazole, clarithromycin plus metronidazole or amoxicillin. It is successful
in 80-90 percent of cases (Marshall et al, 1985). The most common reasons for failure are
antibiotic resistance and poor compliance with treatment.  Resistance to clarithromycin is
increasing and is a crucial determining factor in treatment success. Patients with previous
exposure to clarithromycin should not receive this drug for H. pylori treatment unless an‐
tibiotic susceptibility testing shows that they have a sensitive strain. Metronidazole resist‐
ance is also very common, in particular amongst those having previous exposure to the
drug.
So new research has been developed in natural products with anti HP activity.
When Nigella sativa L. (Ranunculaceae) seeds were given to patients with dyspeptic symp‐
toms and found positive for HP infection in a dose of 2g/d along with 40 mg/d omeprazole,
it possessed clinically useful anti HP activity (O'Mahony et al, 2005). Solamumlyratum‐
Thunp (SLE, Solanaceae) showed a moderate ability in inhibiting growth of HP and its asso‐
ciation with host cells (Enomoto et al, 2010)
Curcumin from turmeric (Curcuma longa, longa, Zingiberaceae) has been lastly shown to
arrest HP growth. Its potential was highly effective in eradication of HP from infected mice
and to restore gastric damage, induced by chemicals like iodoacetamide(Elseweidy et al,
2008, Chowdhury and Mukhopadhyay, 2009). Crude essential oil obtained from the dried
aerial parts of Thymus Caramanicusjalas (Lamiaceae) at a concentration of 0.33 ul/ml was
tested in vitro against clinical isolates and proved to be highly effective.
Aqueous extract of Glucyrrhiza –globra L (Fabaceae) 1mg /ml significantly inhibited the ad‐
hesion of HP to human stomach tissue. The effect was related to the polysaccarIdes isolated
from the extract (Eftekhar et al, 2009)
18. Prospects for future vaccines
The prevalence of antibiotic resistance amongst H. pylori isolates is increasing, and there are
reports of over 50 percent of isolates being resistant to metronidazole in parts of Asia and
Africa (Lwai-Lume et al, 2005, Kim et al, 2006).Such antibiotic resistance is a problem for
many pathogenic bacterial infections, and large scale control of such infections is probably
best achieved through vaccination programmes. Although vaccination appears the logical
approach to control H. pylori, however vaccine research has not been straightforward and
may need extensive efforts to achieve significant results.
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